This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Phase 2 Study of VX-950, Pegasys and Copegus in Hepatitis C

This study has been completed.
Information provided by:
Vertex Pharmaceuticals Incorporated Identifier:
First received: December 2, 2005
Last updated: December 17, 2007
Last verified: December 2007
To assess the safety of the combination of VX-950, Pegasys and Copegus in subjects with hepatitis C.

Condition Intervention Phase
Hepatitis C Drug: VX-950 Drug: ribavirin Drug: peginterferon alfa-2a Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Official Title: A Phase 2 Study of VX-950 in Combination With Peginterferon Alfa-2a (Pegasys®) and Ribavirin (Copegus®) in Subjects With Hepatitis C

Resource links provided by NLM:

Further study details as provided by Vertex Pharmaceuticals Incorporated:

Primary Outcome Measures:
  • Safety of triple combination therapy. [ Time Frame: retrospective and prospective ]

Secondary Outcome Measures:
  • Pharmacokinetics of VX-950, peginterferon alfa-2a and ribavirin. [ Time Frame: retrospective and prospective ]
  • Plasma HCV RNA levels [ Time Frame: retrospective and prospective ]

Estimated Enrollment: 12
Study Start Date: December 2005
Study Completion Date: April 2006

Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Infected with hepatitis C virus

Exclusion Criteria:

  • Contraindications to peginterferon or ribavirin therapy.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00262483

United States, Texas
Call for information
San Antonio, Texas, United States
Puerto Rico
Call for information
Santurce, Puerto Rico
Sponsors and Collaborators
Vertex Pharmaceuticals Incorporated
Study Director: Medical Monitor Vertex Pharmaceuticals Incorporated
  More Information

Responsible Party: Robert Kauffman M.D., Ph.D., Vertex Pharmaceuticals Incorporated Identifier: NCT00262483     History of Changes
Other Study ID Numbers: VX05-950-102
Study First Received: December 2, 2005
Last Updated: December 17, 2007

Additional relevant MeSH terms:
Hepatitis A
Hepatitis C
Liver Diseases
Digestive System Diseases
Hepatitis, Viral, Human
Virus Diseases
Enterovirus Infections
Picornaviridae Infections
RNA Virus Infections
Flaviviridae Infections
Peginterferon alfa-2a
Molecular Mechanisms of Pharmacological Action
Antiviral Agents
Anti-Infective Agents
Immunologic Factors
Physiological Effects of Drugs processed this record on August 18, 2017